Apogee Therapeutics, Inc.
APGE
$41.96
$0.781.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -72.43% | -111.81% | -135.21% | -79.06% | -156.24% |
| Total Depreciation and Amortization | 613.79% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 451.32% | 1,095.19% | 113.75% | 163.97% | 36.73% |
| Change in Net Operating Assets | -124.60% | -336.16% | 1,290.10% | -51.84% | -289.19% |
| Cash from Operations | -53.23% | -127.58% | -113.90% | -101.10% | -199.67% |
| Capital Expenditure | -1,129.91% | 100.60% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 133.66% | 217.31% | 37.82% | -- | -- |
| Cash from Investing | 125.09% | 216.82% | 37.50% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.86% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 1,850.71% | -1,850.71% | -- |
| Cash from Financing | -99.86% | 20,924.41% | -99.88% | 91.15% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -109.50% | 133.03% | -398.29% | -995.41% | 3,577.70% |